<DOC>
	<DOCNO>NCT00003760</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irofulven treat patient stage III stage IV pancreatic cancer surgically remove .</brief_summary>
	<brief_title>Irofulvene Treating Patients With Stage III Stage IV Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine survival rate 6 month patient stage III IV unresectable adenocarcinoma pancreas treat 6-hydroxymethylacylfulvene ( MGI 114 ) . II . Determine objective tumor response rate , time objective tumor response , duration response patient ( retrospective data available , time tumor progression prior gemcitabine determine ) . III . Determine clinical benefit MGI 114 measure pain improvement , performance status , weight . IV . Determine survival rate 3 , 9 , 12 month patient . V. Gain additional information toxic effect safety profile regimen . OUTLINE : This open label , multicenter study . Patients receive 6-hydroxymethylacylfulvene ( MGI 114 ) IV 5 minute day 1-5 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow monthly 1 year therapy initiation . PROJECTED ACCRUAL : A total 50 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage III IV unresectable adenocarcinoma exocrine pancreas Must treat 1 prior gemcitabine regimen , document disease progression either within 6 month completion therapy Measurable evaluable disease outside previously irradiate area No islet cell tumor lymphoma pancreas No significant CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2 mg/dL AST ALT great 2 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No atrial ventricular arrhythmia require medication No atrial fibrillation ( without medication ) No ischemic event within past 6 month No history congestive heart failure Other : Not pregnant nursing Fertile patient must use effective contraception No significant psychiatric disorder No active infection No prior malignancy within past 5 year , except : Basal squamous cell skin cancer Carcinoma situ cervix No concurrent serious systemic disorder PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy No concurrent immunotherapy Chemotherapy : At least 4 week since prior gemcitabine therapy recover No prior chemotherapy ( except fluorouracil radiation enhance agent ) No concurrent chemotherapy Endocrine therapy : No prior hormonal therapy No concurrent hormonal therapy ( except contraceptive , hormone replacement , megestrol acetate ) Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify Other : At least 4 week since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>